CSI Market
Sign In | Register

The Oncology Institute Inc (TOI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TOI Annual Cash Flow →
This cash flow overview for The Oncology Institute Inc spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-22.61
Depreciation & amortization3.45
Amortization of Other Assets3.90
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories3.14
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.03
Share-based Compensation2.76
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.17
Investment Income Interest-
Increase Decrease In Accrued Liabilities Related Parties-
Increase Decrease In Operating Lease Right Of Use Assets-
Segment Assets Written Off-
Derivative Gain Loss On Derivative Net-5.00
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Accounts Receivable7.39
Increase (Decrease) in Accounts Payable17.11
Increase (Decrease) in Accrued Liabilities7.35
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-1.81
Other Working Capital0.07
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-10.82
Discontinued operations0.00
Net Cash flow from Operating Activities9.73
Investing Activities
Capital Expenditures-1.95
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.95
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.11
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.36
Offering Costs Included In Accrued Expenses Incurred During Noncash Or Partial Noncash Transaction-
Deferred Underwriting Commissions In Connection With Initial Public Offering-
Common Stock Subject To Possible Redemption Noncash-
Change In Value Of Common Stock Subject To Possible Redemption-
Proceeds From Offering Costs Paid-
Proceeds From Reverse Recapitalization Transaction-
Payments For Reverse Recapitalization Transaction Costs-
Payments As A Result Of Recapitalization Transaction-
Proceeds From Financing Of Insurance Payments-
Payments For Financing Of Insurance Payments-0.26
Noncash Or Part Noncash Acquisition Value Of Assets Acquired-
Deferred Consideration As Part Of Practice Acquisitions-
Interest And Principal Forgiven From Paycheck Protection Program Loan Cares Act-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.25
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow7.77
Total Cash Flow7.53
4 historic quarters locked

Sign in to unlock the full The Oncology Institute Inc cash flow history.

Sign In Create Free Account

About Starling Oncology Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 6, 2026
  • Source: toi-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001799191-26-000017

Figures are derived from filed reports and may be restated. Historical data is subject to revision.